hostile takeover

NEW YORK (GenomeWeb News) – Following notification by a hedge fund headed by Carl Icahn of its intentions to acquire a stake in Hologic, the Bedford, Mass.-based firm today announced it has adopted a stockholder rights plan "intended to ensure that the board remains in the best position to perfor

This article has been updated with comments from an internal Illumina e-mail.
By a GenomeWeb staff reporter

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Roche today reported that its molecular diagnostics sales increased 4 percent year over year, while its sales for microarrays and genomic sequencing products dropped sharply.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Institutional Shareholder Services, a proxy-advisory firm, today recommended that Illumina's shareholders vote against Roche's slate of nominees for Illumina's board of directors.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) — In its pursuit to acquire Illumina in a hostile takeover, Roche has again turned directly to the company's shareholders, aiming to convince them of the attractiveness of its offer.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Illumina has once again rejected Roche's offer to acquire the firm and is urging its shareholders to also reject Roche's slate of nominees for Illumina's board of directors.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Roche said today that is has raised its cash tender offer for Illumina from $44.50 to $51 per share — an increase of 15 percent — valuing the deal at nearly $6.7 billion.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Roche has extended its $5.7 billion hostile takeover bid for Illumina for another month at the same price, the company said today.

Pages

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.